CoChat

A sporadic Alzheimer's blood-brain barrier model for developing ultrasound-mediated delivery of Aducanumab and anti-Tau antibodies

Open access
Wasielewska, Joanna M., Chaves, Juliana C. S., Johnston, Rebecca L., Milton, Laura A., Hernández, Damián, Chen, Liyu, Song, Jae, Lee, Wendy, Leinenga, Gerhard, Nisbet, Rebecca M., Pébay, Alice, Götz, Jürgen, White, Anthony R., Oikari, Lotta E. · 2022 · Theranostics
Cited by 41

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

Abstract Rationale The blood-brain barrier (BBB) is a major impediment to therapeutic intracranial drug delivery for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD). Focused ultrasound applied together with microbubbles (FUS +MB ) is a novel technique to transiently open the BBB and increase drug delivery. Evidence suggests that FUS +MB is safe, however the effects of FUS +MB on human BBB cells, especially in the context of AD, remain sparsely investigated. Methods Here we generated BBB cells (induced brain endothelial cells (iBECs) and astrocytes (iAstrocytes)) from apolipoprotein E gene allele E4 ( APOE4 , high AD risk) and allele E3 ( APOE3 , lower AD risk) carrying patient-derived induced pluripotent stem cells (iPSCs). We then developed a human sporadic AD BBB cell platform to investigate the effects of FUS +MB on BBB cells and screen for the delivery of two potentially therapeutic AD antibodies. Results We utilized this robust and reproducible human BBB model to demonstrate increased delivery of therapeutic AD antibodies across the BBB following FUS +MB treatment, including an analogue of Aducanumab (Aduhelm TM ; anti-amyloid-β) and a novel anti-Tau antibody RNF5. Our results also demonstrate the safety of FUS +MB indicated by minimal changes in the cell transcriptome as well as little or no changes in cell viability and inflammatory responses within the first 24 h post FUS +MB . Finally, we report a more physiologically relevant hydrogel-based 2.5D BBB model as a key development for FUS +MB -mediated drug delivery screening, with potentially higher translational utility. Conclusion Our results demonstrate an important translatable patient BBB cell model for identifying FUS +MB -deliverable drugs and screening for cell- and patient-specific effects of FUS +MB , accelerating the use of FUS +MB as a therapeutic modality in AD. One Sentence Summary Focused ultrasound increases the in vitro delivery of therapeutic antibodies Aducanumab and anti-Tau in a sporadic Alzheimer’s disease patient-derived blood-brain barrier cell model.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7150/thno.72685

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 41

Metadata

Authors
Wasielewska, J. M., Chaves, J. C. S., Johnston, R. L., Milton, L. A., Hernández, D., Chen, L., Song, J., Lee, W., Leinenga, G., Nisbet, R. M., Pébay, A., Götz, J., White, A. R., & Oikari, L. E.
Venue
Theranostics
Published
2022
Volume
12
Issue
16
Pages
6826-6847
ISSN
1838-7640 (ISSN-L)
OpenAlex
W4307429836
Cited by
41
References
44
FWCI
2.35
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A sporadic Alzheimer's blood-brain barrier model for developing ultrasound-mediated delivery of Aducanumab and anti-Tau antibodies. https://app.cochat.ai/papers/10.7150/thno.72685
The paper
Wasielewska, J. M., Chaves, J. C. S., Johnston, R. L., Milton, L. A., Hernández, D., Chen, L., Song, J., Lee, W., Leinenga, G., Nisbet, R. M., Pébay, A., Götz, J., White, A. R., & Oikari, L. E. (2022). A sporadic Alzheimer's blood-brain barrier model for developing ultrasound-mediated delivery of Aducanumab and anti-Tau antibodies. Theranostics. https://doi.org/10.7150/thno.72685

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.